A pilot study of prostate‐specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer
Abstract
Prostate‐specific membrane antigen (PSMA) is a rational target for noninvasive detection of recurrent prostate cancer (PCa) and for therapy of metastatic castration‐resistant prostate cancer (mCRPC) with PSMA‐targeted agents. Here we conducted serial measurements of PSMA expression on circulating tumor cells (CTCs) to evaluate patterns of longitudinal PSMA dynamics over the course of multiple sequential therapies.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 30, 2019
- Source ID
- 10.1002/pros.23883
Entities
People
- Channing J Paller
- Danilo Piana
- Emmanuel S. Antonarakis
- James R. Eshleman
- Jun Luo
- Mario A. Eisenberger
- Martin G. Pomper
- Pedro Isaacsson Velho
- Samuel Denmeade
- Stacy Riel
- Steven P Rowe
Organizations
- Johns Hopkins University
- National Cancer Institute
- Prostate Cancer Foundation
- United States Department of Defense